Modality
Nanobody
MOA
SGLT2i
Target
RET
Pathway
Checkpoint
CKDCSUOvarian Ca
Development Pipeline
Preclinical
~Mar 2016
→ ~Jun 2017
Phase 1
Sep 2017
→ Oct 2029
Phase 1Current
NCT06188736
63 pts·CKD
2017-09→2029-10·Completed
NCT06091673
201 pts·CKD
2024-02→2027-08·Active
264 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-08-271.4y awayInterim· CKD
2029-10-223.6y awayInterim· CKD
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1
Complet…
P1
Active
Catalysts
Interim
2027-08-27 · 1.4y away
CKD
Interim
2029-10-22 · 3.6y away
CKD
ActiveCompleted|StartCompletionToday
Trials (2)
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| RHH-5389 | Roche | Preclinical | RET | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Motazanubrutinib | Biogen | Preclinical | CD38 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 |